Wei Xin, Li Lingjun
Department of Chemistry, University of Wisconsin, Madison, Wisconsin 53705, USA.
Int J Clin Exp Pathol. 2009;2(2):132-48. Epub 2008 Jun 20.
There is an urgent need to search for biomarkers that are indicative of neurodegenerative diseases, as the clinical diagnosis of which remains unsatisfactory. Mass spectrometry (MS) has been playing an important role in studying peptide and protein identities, structures, modifications and interactions that collectively drive their biological functions. MS-based proteomics technology is thus well suited for the biomarker discovery. This article reviews the overall strategies and workflows employed for biomarker discovery and recent applications of MS-based proteomics in neurodegenerative diseases. Special emphasis is placed on the studies of protein post-translational modification pattern changes and differential peptidomics under these pathological conditions.
由于神经退行性疾病的临床诊断仍不尽人意，因此迫切需要寻找能够指示这些疾病的生物标志物。质谱（MS）在研究共同驱动其生物学功能的肽和蛋白质的身份、结构、修饰及相互作用方面一直发挥着重要作用。基于质谱的蛋白质组学技术因此非常适合用于生物标志物的发现。本文综述了用于生物标志物发现的总体策略和工作流程，以及基于质谱的蛋白质组学在神经退行性疾病中的最新应用。特别强调了在这些病理条件下蛋白质翻译后修饰模式变化和差异肽组学的研究。
